Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 7/20 | 0.34 |
| ▸ | ACHE | P22303 | 7/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.32 |
| ▸ | MLYCD | O95822 | 1/20 | 0.31 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | POLQ | O75417 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12457520 | 0.82 | BCHE (0.36) | HDAC4HDAC6BCHEACHERAB9A | |
| SCHEMBL16330628 | 0.79 | HDAC4 (0.37) | HDAC4HDAC6BCHEACHEMEN1 | |
| SCHEMBL19251150 | 0.79 | FAAH (0.37) | HDAC4HDAC6BCHEACHERAB9A | |
| SCHEMBL18505712 | 0.78 | HDAC4 (0.37) | HDAC4HDAC6BCHEACHEKMT2A | |
| SCHEMBL12459141 | 0.77 | LMNA (0.43) | RAB9ASMN1; SMN2CACNA1I | |
| SCHEMBL25096492 | 0.74 | SMN1; SMN2 (0.45) | MEN1KMT2ASMN1; SMN2CYP2C19 | |
| SCHEMBL16819725 | 0.74 | RXRA (0.41) | HDAC4HDAC6MEN1RAB9AKMT2A | |
| SCHEMBL4692646 | 0.74 | HDAC4 (0.49) | HDAC4HDAC6MEN1RAB9AKMT2A | |
| SCHEMBL12459152 | 0.73 | CACNA1I (0.37) | RAB9ATRPV1SMN1; SMN2CACNA1ICYP2C19 | |
| SCHEMBL13765816 | 0.73 | HTT (0.44) | RAB9AKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10865216-B2 | Tricyclic Gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-12-15 | — | — | US | disclosed |
| US-10858360-B2 | Tricyclic gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-12-08 | — | — | US | disclosed |
| US-20170369498-A1 | TRICYCLIC GYRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-12-28 | — | — | US | disclosed |
| US-9732083-B2 | Tricyclic gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9732083-B2 | Tricyclic gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-15 | — | — | US | disclosed |
| US-20150246934-A1 | TRICYCLIC GYRASE INHIBITORS | MERCK SHARP & DOHME LLC | 2015-09-03 | — | — | US | disclosed |
| US-20120238751-A1 | TRICYCLIC GYRASE INHIBITORS | TRIUS THERAPEUTICS, INC. (US) | 2012-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238751-A1 | TRICYCLIC GYRASE INHIBITORS | TOP1, TOP2A, TOP2B | HDAC4 776/4885HDAC6 836/4885BCHE 947/4885 |
| US-20150246934-A1 | TRICYCLIC GYRASE INHIBITORS | TOP1, TOP2A, TOP2B | HDAC4 1046/4885HDAC6 892/4885BCHE 731/4885 |
| US-10858360-B2 | Tricyclic gyrase inhibitors | TOP1, TOP2A, TOP2B | HDAC4 776/4885HDAC6 836/4885BCHE 947/4885 |
| US-20170369498-A1 | TRICYCLIC GYRASE INHIBITORS | TOP1, TOP2A, TOP2B | HDAC4 776/4885HDAC6 836/4885BCHE 947/4885 |
| US-10865216-B2 | Tricyclic Gyrase inhibitors | TOP1, TOP2A, TOP2B | HDAC4 1046/4885HDAC6 892/4885BCHE 731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.